PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of “Moderate Buy” from Analysts
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Lucid Diagnostics Q4 Earnings Call Highlights
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
Lucid Diagnostics (NASDAQ:LUCD) & Alpha Tau Medical (NASDAQ:DRTS) Financial Survey
Inogen (INGN) Soars 6.6%: Is Further Upside Left in the Stock?
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
Contrasting Lucid Diagnostics (NASDAQ:LUCD) & Waters (NYSE:WAT)
Reviewing Intuitive Surgical (NASDAQ:ISRG) and Lucid Diagnostics (NASDAQ:LUCD)
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of “Moderate Buy” by Brokerages
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
What Makes Lucid Diagnostics Inc. (LUCD) a Strong Momentum Stock: Buy Now?
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript